This is an investigational study. DA-EPOCH is commercially available and FDA-approved for the treatment of Burkitt leukemia and ALL. Ofatumumab and rituximab are commercially available and FDA-approved for the treatment of some types of chronic lymphocytic leukemia (CLL). It is considered investigational to add ofatumumab to DA-EPOCH to treat Burkitt leukemia and ALL. The study doctor can explain how the study drugs are designed to work.